No Data
Adaptive Biotechnologies Analyst Ratings
BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $9
Adaptive Biotechnologies Gains Positive Outlook With Strategic Advancements and Increased ClonoSEQ Utilization
New Strategy? Cathie Wood's ARK Purchases Shares in Futu, Significantly Increased Its Stake in AI Healthcare Company Tempus AI and Sold Off Shopify
Cathie Wood's ARK ETF announced the daily Trade details for Tuesday, December 17, 2024.
Top 3 Health Care Stocks That May Collapse This Quarter
Even After Rising 6.5% This Past Week, Adaptive Biotechnologies (NASDAQ:ADPT) Shareholders Are Still Down 77% Over the Past Five Years